29
298060.KQ SCM Lifescience Co. Ltd
- Market cap
- KRW 22.6B
- P/E
- -
- P/B
- 0.70x
- ROE
- -35.8%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 298060.KQ undervalued?
Graham numberThe Graham number of SCM Lifescience Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SCM Lifescience Co. Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-35.8%), below 10%.
ROA 0/1
Return on assets (-24.1%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (103.8%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 291.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash runway cannot be calculated.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.7x) is below the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
SCM Lifescience Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SCM Lifescience Co. Ltd
POONGJEON PHARMACY CO.,LTD. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was formerly known as SCM Lifescience Co., Ltd. and change its name to POONGJEON PHARMACY CO.,LTD. in April 2026. The company was incorporated in 2014 and …
Full company profileSCM Lifescience Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SCM Lifescience Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 29.6M | 28.8M | 168M | 320M | 439M | 396M | 696M | 825M | 23.8B | 54.5B |
| Gross Profit | 14.7M | 20.9M | 130M | 277M | 348M | 176M | 339M | 327M | 4.41B | 14.2B |
| Operating Income | -5.32B | -8.57B | -12.2B | -16.1B | -12.1B | -12.6B | -13.0B | -11.2B | -4.53B | -4.94B |
| EBITDA | - | - | - | - | - | -21.7B | -22.8B | -11.9B | 1.69B | -8.53B |
| Net Income | -1.74B | -40.1B | -42.6B | -9.63B | -22.5B | -22.9B | -24.0B | -12.4B | 203M | -11.6B |
| EPS | -194 | -4,379 | -4,639 | -811 | -1,386 | -1,400 | -1,171 | -605 | 23 | -1,307 |
| Balance Sheet | ||||||||||
| Total Assets | 6.44B | 43.9B | 41.0B | 76.3B | 54.0B | 33.0B | 25.4B | 23.2B | 52.0B | 48.0B |
| Total Liabilities | 15.1B | 88.5B | 24.2B | 13.2B | 9.43B | 8.51B | 4.93B | 8.99B | 15.9B | 15.7B |
| Shareholders' Equity | -8.67B | -44.6B | 16.9B | 63.1B | 44.6B | 24.5B | 20.5B | 14.2B | 36.1B | 32.3B |
| Cash & Short-term Investments | 5.06B | 38.5B | 22.5B | 34.2B | 18.9B | 6.92B | 4.50B | 920M | 6.96B | 4.81B |
| Total Debt | 8.00B | 23.2B | 6.59B | 6.19B | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -4.99B | -6.56B | -8.42B | -10.9B | -13.4B | -11.2B | -12.1B | -10.1B | -5.30B | - |
| Capital Expenditure | 282M | 1.09B | 9.28B | 1.48B | 676M | 505M | 244M | 4.38B | 4.69B | 68.9M |
| Free Cash Flow | - | - | -17.5B | -12.4B | -14.1B | -11.7B | -12.4B | -14.4B | -9.99B | - |
| Ratios | ||||||||||
| ROE | - | - | -252.5% | -15.3% | -50.5% | -93.5% | -117.0% | -87.3% | 0.6% | -35.8% |
| ROA | -27.1% | -91.4% | -103.7% | -12.6% | -41.7% | -69.4% | -94.3% | -53.4% | 0.4% | -24.1% |
| Net Profit Margin | -5,882.0% | -139,404.5% | -25,254.5% | -3,010.2% | -5,126.5% | -5,790.7% | -3,444.2% | -1,500.6% | 0.8% | -21.2% |
| Debt to Equity | - | - | 0.39x | 0.10x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
SCM Lifescience Co. Ltd dividends
SCM Lifescience Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on May 19, 2026.
Who owns SCM Lifescience Co. Ltd
- Insiders 64.82%
- Institutions 0.00%
- Public & others 35.18%
- Shares outstanding 9.64M
- Free float 534K
SCM Lifescience Co. Ltd company profile
- Company name
- SCM Lifescience Co. Ltd
- Ticker
- 298060.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Fiscal year end
- December
- Address
- 7-7, Gaetbeol-ro 145beon-gil, Incheon, South Korea, 21999
- Phone
- 82 3 2881 3600
- Website
- scmlifescience.com
About SCM Lifescience Co. Ltd
POONGJEON PHARMACY CO.,LTD. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was formerly known as SCM Lifescience Co., Ltd. and change its name to POONGJEON PHARMACY CO.,LTD. in April 2026. The company was incorporated in 2014 and is headquartered in Incheon, South Korea.
SCM Lifescience Co. Ltd management
5- Byeong-gwan SonCEO & Chairman
- Mr. Sun-uk SongFounder, CSO & VP
- Mr. Sukwoo Jeffrey Oh J.D.Chief Operating Officer
- Jong-cheol LeeExecutive Director
- Hyeong-nam OhExecutive Director